Clinical Trials Browser

Phase 3 × Fulvestrant × 90 days × Clear all

NCT00099437 2026-03-18

CONFIRM

Phase 3 Active not recruiting

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

Phase 3 Active not recruiting

624 enrolled 17 charts

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

Phase 3 Recruiting

Breast Neoplasms

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06982521 2026-03-03

ReDiscover-2

Phase 3 Recruiting

Breast Neoplasms

NCT01602380 2026-02-27

FALCON

Phase 3 Completed

462 enrolled 20 charts

Neoplasm Metastasis, Neoplasms

NCT05038735 2026-02-20

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT05696626 2026-01-26

ELAINEIII

Phase 3 Recruiting

Breast Neoplasms

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Phase 3 Active not recruiting

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT05169567 2026-01-16

postMONARCH

Phase 3 Active not recruiting

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT06635447 2026-01-13

CAPItrue

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

NCT06764186 2026-01-13

CAPItana

Phase 3 Active not recruiting

Breast Neoplasms

NCT05365178 2026-01-07

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Phase 3 Active not recruiting

HR-positive, HER2-negative Breast Neoplasms

NCT07207070 2025-12-30

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

Breast Neoplasms